FDA Rejects Promising Lung Cancer Drug Despite 48% Reduction in Risk of Disease Progression or Death
Summary
The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.
Description from Ibtimes.
Who is covering this
-
FDA Rejects Promising Lung Cancer Drug Despite 48% Reduction in Risk of Disease Progression or Death
The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.





Comments
Comments need JavaScript.